MEDICINOVA INC

MediciNova, Inc. announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application. This patent covers the use of ibudilast (MN-166) in combination with an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for treating glioblastoma. This development is expected to strengthen the company's intellectual property position for its combination therapy development strategy, with the patent expiring no earlier than September 2042.

MediciNova, Inc. announced the completion of the last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202. This trial is evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The randomized, double-blind, placebo-controlled study involved patients receiving either 500 mg/day of MN-001 or placebo for 24 weeks. Top-line data from the trial are anticipated in the third quarter of 2026.

MediciNova reported a net loss of $2.59 million for the first quarter of 2026, an improvement from a $2.86 million net loss in the prior year. The company generated $186,984 in revenue, primarily from clinical research services for MN-166 (ibudilast) in ALS, compared to no revenue in the same period last year. Operating expenses decreased, contributing to a reduced operating loss. The company also terminated its ATM agreement and has new equity distribution agreements in place, though no shares were sold under them in Q1 2026.

MediciNova, Inc. announced its 2026 Annual Meeting of Stockholders will be held on June 23, 2026. Key proposals include the election of two Class I directors, the ratification of BDO USA, P.C. as the independent auditor, and a significant amendment to increase the authorized common stock from 100,000,000 to 247,000,000 shares. This increase aims to provide the company with greater flexibility for future equity incentive plans, financing transactions, and strategic activities.

MediciNova, Inc. announced that a study published in "Cancer Research" identified a central vulnerability in brain metastasis and demonstrated the potential of its lead product, MN-166 (ibudilast), to address it. The research showed that MN-166 can effectively block MIF–CD74 signaling, reverse pro-metastatic immune reprogramming, and suppress brain metastasis growth in preclinical systems. These findings provide a strong rationale for pursuing biomarker-driven clinical strategies, and MediciNova plans to collaborate on future clinical research for patients with brain metastases.